CATIE contd.

The Pharma press releases are coming in thick and fast!

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-19-2005/0004110510&EDATE=

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-19-2005/0004110384&EDATE=

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-21-2005/0004112384&EDATE=

http://www.eurekalert.org/pub_releases/2005-09/niom-nst091905.php

Scores so far........ 1 for Eli Lilly : 0 for AstraZeneca!

But there is a "hidden" reason why Lillys' Zyprexa might have shaved an advantage. When the clinical trial was designed, it was decided that patients in CATIE receiving Zyprexa could receive a dose that is higher than that recommended on the drug’s label. But that is not true for the others. If Zyprexa does come out ahead, competitors will jump all over this fact.

Insiders guess is that Pfizers' Geodon will make the most of the lack of weight gain.

Risperdal and Seroquel have yet to find an upside!

Here is the NEJM abstract (all that's read by many!):

http://content.nejm.org/cgi/content/short/353/12/1209